

FACSIMILE COVER SHEET

FILE COPY**SALIWANCHIK, LLOYD & SALIWANCHIK**

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

COMPANY: U.S. Patent Office**FROM:** David R. Saliwanchik**DEPARTMENT:** Office of Initial Patent
Examination's Filing Receipt Corrections**DATE:** June 28, 2004**FAX NO.:** (703) 746-9195**NO. OF PAGES**
(INCLUDING COVER SHEET): 8**SUBJECT/MESSAGE:**

Re: Serial No. 10/763,904; filed January 23, 2004
Attorney Docket No. ARYX-101XCD2

- 1) Request for Corrected Official Filing Receipt with attachments.

THIS IS AN OFFICIAL DOCUMENT!

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

H:\DOC\FAXCOVER\PTO\OFR-CORRECT.DOC\RES\la

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

Patent Application
Docket No. ARYX-101XCD2
Serial No. 10/763,904

June 28, 2004
David Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Pascal Druzgala, Peter G. Milner
Serial No. : 10/763,904
Filed : January 23, 2004
Conf. No. : 7766
For : Ultrashort Acting Hypnotic Barbiturates

Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The applicants respectfully request the correction of a clerical error in the Official Filing Receipt for the above-identified patent application. The error has occurred in the Domestic Priority data as claimed by applicants section: The correction needed is as follows:

Domestic Priority data as claimed by applicant

This application is a CON of 10/145,601 05/13/2002 PAT 6,683,086
which is a CON of 09/841,738 04/24/2001 PAT 6,387,914


Should Read:

This application is a CON of 10/145,601 05/13/2002 PAT 6,683,086
which is a CON of 09/841,738 04/24/2001 PAT 6,387,914, which
claims the benefit of 60/199,144 04/24/2000

Docket No. ARYX-101XCD2
Serial No. 10/763,904

A copy of the Provisional Application for Patent Cover Sheet, Certificate of Mailing by Express Mail, as well as a marked-up copy of the erroneous Official Filing Receipt accompanies this Request. Correction of the above is respectfully requested.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/la

Enclosures: Copy of first page of subject application;
Copy of executed Declaration and Power of Attorney; and
Copy of marked-up erroneous Official Filing Receipt.

H:\DOC\OF\ARYX-101XCD2-PTO-DOC\DNB\la



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	.FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/763,904	01/23/2004	1624	385	ARYX-101XCD2	3	1	1

CONFIRMATION NO. 7766

23557

SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
2421 N.W. 41ST STREET
SUITE A-1
GAINESVILLE, FL 326066669



FILING RECEIPT



OC000000012473910

Date Mailed: 04/30/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Pascal Druzgala, Santa Rosa, CA;
Peter G. Milner, Los Altos Hills, CA;

Domestic Priority data as claimed by applicant

This application is a CON of 10/145,601 05/13/2002 PAT 6,683,086
which is a CON of 09/841,738 04/24/2001 PAT 6,387,914

Foreign Applications

If Required, Foreign Filing License Granted: 04/28/2004

Projected Publication Date: 08/05/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Ultrashort acting hypnotic barbiturates

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

1

ARYX-101XCD2

DESCRIPTIONULTRASHORT ACTING HYPNOTIC BARBITURATES

5

Cross-Reference to Related Application

This application is a continuation of co-pending application U.S. Serial No. 10/145,601, filed May 13, 2002; which is a continuation of application U.S. Serial No. 09/841,738, filed April 24, 2001, now U.S. Patent No. 6,387,914. This application also claims the benefit of U.S. Provisional Application No. 60/199,144, filed April 24, 2000.

10

Background of the Invention

15

The principal use of a sedative-hypnotic drug is to produce drowsiness and to promote sleep. Since sedative-hypnotic drugs usually have the capacity of producing widespread depression of the CNS, these drugs are employed for various reasons, including as antiepileptic, muscle relaxants, antianxiety drugs, and even to produce amnesia or general anesthesia. Throughout the world, more prescriptions are written for sedative-hypnotic-antianxiety drugs than for any other class of drugs.

20

Barbiturates have enjoyed a long period of extensive use as sedative-hypnotic drugs. However, except for a few specialized uses, they have been largely replaced by the somewhat safer benzodiazepines.

25

The barbiturates reversibly depress the activity of all excitable tissues. Not all tissues are affected at the same dose or concentration. The CNS is the most sensitive to the action of barbiturates. When barbiturates are given in sedative or even hypnotic doses, there is very little effect on skeletal, cardiac, or smooth muscle. Even in anesthetic concentrations, peripheral effects are weak and do not create difficulties if the duration of anesthesia is not prolonged. However, if depression is extended, serious deficits in cardiovascular and other peripheral functions can occur.

30

Barbituric acid (2,4,6-trioxohexahydropyrimidine) and its analog thiobarbituric acid, lack central depressant activity, but the presence of alkyl or aryl groups at position-5 confers sedative-hypnotic and sometimes other activities. The

J:\SH-APPS\ARYX\ARYX-101XCD2.doc/DNB/la